Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 3
1957 7
1958 2
1960 2
1961 1
1963 1
1964 2
1965 2
1966 4
1967 5
1968 1
1969 8
1970 5
1971 8
1972 4
1973 10
1974 10
1975 4
1976 5
1977 8
1978 1
1979 8
1980 8
1981 12
1982 5
1983 12
1984 9
1985 12
1986 9
1987 6
1988 7
1989 9
1990 8
1991 7
1992 6
1993 10
1994 12
1995 12
1996 14
1997 7
1998 6
1999 6
2000 3
2002 8
2003 1
2004 4
2005 4
2006 3
2007 1
2008 3
2009 3
2010 3
2011 3
2012 4
2013 6
2014 18
2015 10
2016 9
2017 7
2018 10
2019 12
2020 13
2021 13
2022 11
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Ramanathan S, et al. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15. J Neurol Neurosurg Psychiatry. 2018. PMID: 29142145 Free PMC article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Propranolol.
Parratt JR. Parratt JR. Lancet. 1967 Apr 29;1(7496):955-6. doi: 10.1016/s0140-6736(67)91518-8. Lancet. 1967. PMID: 4164415 No abstract available.
Response regarding CLIPPERS.
Kossard S, Smith A, Matthews Y, Turner J, Buckland ME, Parratt J. Kossard S, et al. Among authors: parratt j. J Cutan Pathol. 2014 Sep;41(9):761. doi: 10.1111/cup.12360. Epub 2014 Jun 30. J Cutan Pathol. 2014. PMID: 24979349 No abstract available.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Castillo-Triviño T, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T. Sharmin S, et al. Among authors: parratt j. Brain. 2023 Nov 2;146(11):4633-4644. doi: 10.1093/brain/awad218. Brain. 2023. PMID: 37369086 Free PMC article.
5-Hydroxytryptamine in pineapples.
FOY JM, PARRATT JR. FOY JM, et al. Among authors: parratt jr. J Pharm Pharmacol. 1961 Jun;13:382-3. doi: 10.1111/j.2042-7158.1961.tb11840.x. J Pharm Pharmacol. 1961. PMID: 13701135 No abstract available.
A new era in the treatment of multiple sclerosis.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. Broadley SA, et al. Among authors: parratt j. Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. doi: 10.5694/mja14.01218. Med J Aust. 2015. PMID: 26224184 Review.
409 results